Replies to post #10472 on China Unlimited

[growacet]

Resverlogix RVXCF attracts more investment from China....

According to filings the recent PP that took place last week involved an investor (or investors) from China. And of course Chinese Pharma giant Shenzhen Hepalink already owns about 43% of this Phase III company. For those unaware Shenzhen Hepalink is the world's biggest producer of Heparin Sodium, a blood thinner.

Rothschild & Co has been engaged to help Resverlogix, which is listed on Canada's big board Toronto Stock Exchange (symbol RVX) in seeking a listing on a US exchange. Because Resverlogix isn't listed on an American exchange its shares trade OTC in the states.

I can't imagine a company of Rothschild & Co's stature would take on a small Canadian biotech as a client unless there was huge potential...

Phase III trial results are due in and around 6 months time...its an event based trial that is attempting to prove that the company's lead compound Apabetalone will reduce the time to a Major Adverse Cardiac Event (MACE) in patients with Diabetes Mellitus (full blown insulin dependent) who are at extreme high risk of an event like a stroke or heart attack.

The trial will conclude after 250 such MAC events. If the results confirm what was seen in earlier Phase II trials, then I see Apapbetalone as having billion dollar potential and for Resverlogix to soar to a valuation in the billions.